A practical reference on Preclinical research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
==== Albums and EPs ==== Chain, a 1989 album by Paul Haig Chain (The Family Stand album), 1990 Chain (Pylon album), 1990 Chains (album), by Yōko Oginome, 1997 Chain (Bonnie Pink EP), 2008 Chain (KAT-TUN album), 2012 Chain (NCT 127 EP), 2018
February 22, 2013: Bermuda In its National Economic Report of Bermuda for 2012, the Bermudan Ministry of Finance expects GDP will decline by 0% to 1.5% in 2013 but five years of recession will end with "modest growth in 2014". GDP is thought to have contracted by 1.75% to 2.25% in 2012 after a decline of 2.8% in 2011.
Puffballs are a type of fungus featuring a ball-shaped fruiting body that, when mature, bursts on contact or impact, releasing a cloud of dust-like spores into the surrounding area. Puffballs belong to the division Basidiomycota and encompass several genera, including Calvatia, Calbovista and Lycoperdon. The puffballs were previously treated as a taxonomic group called the Gasteromycetes or Gasteromycetidae, but they are now known to be a polyphyletic assemblage. The distinguishing feature of all puffballs is that they do not have an open cap with spore-bearing gills. Instead, spores are produced internally, in a spheroidal fruit body called a gasterothecium (gasteroid 'stomach-like' basidiocarp). As the spores mature, they form a mass called a gleba in the centre of the fruitbody that is often of a distinctive color and texture. The basidiocarp remains closed until after the spores have been released from the basidia. Eventually, it develops an aperture, or dries, becomes brittle, and splits, and the spores escape. The spores of puffballs are statismospores rather than ballistospores, meaning they are not forcibly extruded from the basidium. Puffballs and similar forms are thought to have evolved convergently (that is, in numerous independent events) from Hymenomycetes by gasteromycetation, through secotioid stages. Thus, 'Gasteromycetes' and 'Gasteromycetidae' are now considered to be descriptive, morphological terms (more properly gasteroid or gasteromycetes, to avoid taxonomic implications) but not valid cladistic terms.
Historical novels like Ryōtarō Shiba's Tobu ga Gotoku mention characters like Saigō Takamori enjoying TKG (though likely fictionalized). An essay by Shōtarō Ikenami describes the Forty-seven Rōnin eating a version with duck and negi (historical accuracy uncertain). The book 365 Nichi Tamago Kake Gohan no Hon (2007) introduced 365 variations and popularized the abbreviation "TKG" for creative tamago kake gohan recipes. The idol group Nama Ham to Yaki Udon has a song titled "Tamago Kake Gohan" (2015).
Sources: en.wikipedia.org
2003 First evidence that aging of nematodes is regulated via TOR signaling. 2003 The Methuselah Foundation is organized by Aubrey de Grey and David Gobel to create life extension technologies based on the Strategies for engineered negligible senescence (SENS) approaches and supporting related research in other organizations. 2003 Andrzej Bartke created a mouse that lived 1,819 days (8 days short of 5 years), while the maximum lifespan for this species is 1,030–1,070 days. By human standards, such longevity is equivalent to about 180 years. 2004 First evidence that aging of nematodes is regulated by AMP-Kinase. 2004 Aubrey de Grey coined the term "longevity escape velocity" (LEV). Though the concept per se has been present in the life extension community since at least the 1970s (for example, Robert Wilson, essay Next Stop, Immortality, 1978). 2004 As a result of the use of anti-aging therapy, a team of scientists led by Stephen Spindler managed to extend the life of a group of already adult mice to an average of 3.5 years. For this achievement, the first Methuselah Mouse Rejuvenation 'M Prize' was awarded. 2004 Creation of the first curated database of genes related to human ageing: GenAge. 2006 Creation of induced stem cells (iSC) from somatic cells by the simultaneous action of several factors. First produced by the Japanese scientist Shinya Yamanaka. In 2012, Shinya Yamanaka and John Gurdon received the Nobel Prize for their work on reprogramming mature cells into pluripotent cells. 2007 Extension of mouse lifespan via deletion of insulin receptor in the brain.
He played Sigmund Freud's father in Freud: The Secret Passion (1962) with Montgomery Clift in the lead. He was also well known for his story-telling skills, particularly in reinterpreting the Bible. His best-known book, also a television series, is The Book of Witnesses (1971), in which he turned the Gospels into a series of monologues. He also retold dozens of Old Testament and Apocrypha stories in Bible Stories (1968).
A study by Kim et al. investigated the nutritional value of S. mutilans hoping to extend the application of this species from traditional medicine only. Nutritional analysis on this species found that it is high in crude protein (around 55%) and fat (around 26-30%). Essential amino acids were present, with lysine being the most common (around 3.5% of all essential amino acids), and glutamic acid being the most common nonessential amino acid present in the centipede (around 7% of all nonessential amino acids). Unsaturated fatty acids were also present, with oleic acid being the most common (around 41-48%). Mercury was found, but the concentration was below food safety limits. Pathogenic microorganisms were not found in the centipede samples. From these findings, the researchers suggested that S. mutilans has the potential to be a medicine and food ingredient.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.